Charles River Laboratories International (NYSE:CRL) Shares Up 6.9% – Still a Buy?

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) traded up 6.9% on Wednesday . The company traded as high as $199.83 and last traded at $199.4240. Approximately 82,970 shares changed hands during trading, a decline of 91% from the average session volume of 913,393 shares. The stock had previously closed at $186.60.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of recent analyst reports. Weiss Ratings downgraded Charles River Laboratories International from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 16th. JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Monday, April 13th. Evercore reiterated an “outperform” rating and issued a $220.00 price objective on shares of Charles River Laboratories International in a research note on Friday, May 8th. Royal Bank Of Canada started coverage on shares of Charles River Laboratories International in a report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 price objective on the stock. Finally, Barclays upped their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Charles River Laboratories International Price Performance

The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The company has a market cap of $10.24 billion, a price-to-earnings ratio of -56.56, a price-to-earnings-growth ratio of 2.31 and a beta of 1.46. The company has a fifty day simple moving average of $176.29 and a two-hundred day simple moving average of $183.13.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. During the same quarter in the previous year, the company posted $2.34 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of CRL. Tema Etfs LLC acquired a new position in shares of Charles River Laboratories International during the 4th quarter worth approximately $26,000. Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter worth $42,000. Sfam LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter worth $43,000. Activest Wealth Management lifted its position in shares of Charles River Laboratories International by 10,900.0% in the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $46,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.